Edesa Biotech Inc (EDSA)
NASDAQ:EDSA
Top Page
Edesa Biotech
(NASDAQ:EDSA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$6.00
▲(305.41% Upside)
Action:ReiteratedDate:03/08/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn). Technicals are strong with price well above moving averages and positive MACD, but elevated RSI suggests the move may be overextended. A positive catalyst is the reported Phase 3 clinical data, which supports the pipeline outlook, while valuation remains constrained by negative earnings and no dividend.
Positive Factors
Late-stage clinical success
Statistically significant Phase 3 mortality reduction materially lowers clinical and regulatory risk for paridiprubart. Consistent benefit across severities, provisional patents and manufacturing scale-up point to a credible path to approval and commercial readiness, improving long-term commercialization prospects.
Negative Factors
No commercial revenue
The company remains development-stage with no product sales, meaning intrinsic value depends on clinical and regulatory outcomes. Absent revenue, ongoing losses consume capital and force external financing; commercial execution risk will determine if R&D investment translates to sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical success
Statistically significant Phase 3 mortality reduction materially lowers clinical and regulatory risk for paridiprubart. Consistent benefit across severities, provisional patents and manufacturing scale-up point to a credible path to approval and commercial readiness, improving long-term commercialization prospects.
Read all positive factors
Edesa Biotech (EDSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$44.50M
Dividend YieldN/A
Average Volume (3M)93.40K
Price to Earnings (P/E)―
Beta (1Y)-0.74
Revenue GrowthN/A
EPS Growth30.29%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.28
Shares Outstanding8,348,161
10 Day Avg. Volume65,583
30 Day Avg. Volume93,401
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-319.26
Enterprise Value/Ebitda-4.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Edesa Biotech Business Overview & Revenue Model
Company Description
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoc...
How the Company Makes Money
null...
Edesa Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -101.62K | -119.27K | -186.05K | -183.47K | -118.19K | -118.79K |
| EBITDA | -7.77M | -7.07M | -5.98M | -8.19M | -17.43M | -13.22M |
| Net Income | -7.82M | -7.19M | -6.17M | ― | -17.55M | -13.34M |
Balance Sheet | ||||||
| Total Assets | 14.71M | 13.53M | 3.81M | 8.89M | 11.58M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 12.05M | 10.79M | 1.04M | 5.36M | 7.09M | 7.84M |
| Total Debt | 0.00 | 0.00 | 19.87K | 94.49K | 18.98K | 99.32K |
| Total Liabilities | 756.16K | 1.08M | 1.83M | 1.84M | 2.18M | 1.53M |
| Stockholders Equity | 13.95M | 12.45M | 1.98M | 7.05M | 9.39M | 13.06M |
Cash Flow | ||||||
| Free Cash Flow | -7.94M | -7.32M | -4.89M | -6.64M | -12.28M | -13.67M |
| Operating Cash Flow | -7.94M | -7.32M | -4.89M | -6.64M | -12.28M | -13.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -5.66K | -6.15K |
| Financing Cash Flow | 18.59M | 17.03M | 592.03K | 4.83M | 11.63M | 14.17M |
Edesa Biotech Technical Analysis
Neutral
1.48
Price Trends
3.26
Positive
2.44
Positive
2.37
Positive
Market Momentum
0.89
Positive
50.85
Neutral
14.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDSA, the sentiment is Neutral. The current price of 1.48 is below the 20-day moving average (MA) of 6.23, below the 50-day MA of 3.26, and below the 200-day MA of 2.37, indicating a neutral trend. The MACD of 0.89 indicates Positive momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 14.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EDSA.
Edesa Biotech Risk Analysis
Edesa Biotech disclosed 55 risk factors in its most recent earnings report. Edesa Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Edesa Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $44.50M | -1.26 | -55.75% | ― | ― | 30.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $55.33M | -4.54 | -59.29% | ― | -44.31% | -34.17% | |
| ― | $6.28M | -5.83 | ― | ― | ― | 65.45% | |
45 Neutral | $13.78M | -1.68 | -94.94% | ― | ― | 49.10% | |
| ― | $10.18M | -0.38 | -94.79% | ― | ― | 84.44% |
* Healthcare Sector Average
EDSA
Edesa Biotech
5.33
2.89
118.44%
ERNA
Eterna Therapeutics
0.19
-2.48
-92.92%
LPCN
Lipocine
7.58
4.40
138.36%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.61
-2.17
-45.40%
COCP
Cocrystal Pharma
1.00
-0.42
-29.58%
BIVI
BioVie
1.35
-8.45
-86.22%
Edesa Biotech Corporate Events
Business Operations and StrategyProduct-Related Announcements
Edesa Biotech Reports Positive Phase 3 Paridiprubart Results
Positive
Feb 24, 2026
On February 24, 2026, Edesa Biotech reported additional positive Phase 3 data for paridiprubart from a 278-patient study, showing a statistically significant reduction in adjusted 28-day mortality to 24% from 33% versus placebo across the full tre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.